Technical briefs on amphetamine-type stimulants (ATS). by unknown
The interventions described in this brief adhere to internationally accepted principles 
of drug treatment,1 are evidence based and reflect a public health perspective. 
These are alternatives proposed to the predominantly law-enforcement approaches 
to ATS use currently common in the Asia–Pacific region. Medical interventions for 
the treatment of physical and mental health problems are described, as well as 
psychosocial treatment approaches including community-based interventions.
Introduction
The main objectives of therapeutic interventions for ATS users are to enable them to cease high-
risk and harmful ATS use and address their health-care needs. Research2 has shown that most 
psychostimulant users, especially younger users, do not access treatment services, and most are 
unaware of such services when they do exist. ATS users are reluctant to attend specialist drug 
services and are more likely to initially seek help from nongovernmental organizations (NGO) 
or within the primary health-care system. NGO and primary health-care workers are in a unique 
position to provide services for ATS users as their services are accessed by a broad cross-section 
of the community, so drug users need not feel stigmatized while seeking counselling and other 
interventions. Evidence3 has shown that services for ATS users are best provided in the context of 
existing primary health-care services and NGO/welfare services such as drop-in centres for drug 
users, and not as “stand-alone” services or in compulsory/residential centres for which there is no 
evidence of effectiveness. 
 
Therapeutic interventions
Because of the diversity of ATS users and their drug-use patterns, interventions must be equally 
diverse and varied, and should depend on the extent and severity of the problems experienced 
by users. Below are recommendations for a step-by-step approach, which begins and ends in 
the community but may require highly skilled specialist care for severe problems resulting from 
substance use. To date, there is no evidence-based pharmacological treatment that is suitable for 
ATS users (i.e. substitution therapy).4
To meet the challenge of ATS treatment, an eclectic “stepped-care approach”5 has been developed 
which aims to provide individualized, evidence-based and voluntary treatment. The “stepped-care” 
1	 UNODC/WHO.	Principles of drug dependence treatment: discussion paper.	March	2008.	 (http://www.
unodc.org/documents/drug-treatment/UNODC-WHO-Principles-of-Drug-Dependence-Treatment-
March08.pdf,	accessed	on	02	January	2011).	
2	 Adapted	 from:	The optimal mix of services for mental health. WHO,	Geneva,	2007.	 (http://www.who.
int/mental_health/policy/services/2_Optimal%20Mix%20of%20Services_Infosheet.pdf,	 accessed	 01	
January	2011).
3	 World	 Health	 Organization.	mhGAP Intervention Guide for mental, neurological and substance use 
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approach uses psychosocial interventions at various stages 
of drug use. It aims to increase access to treatment, provide 
support to help users reduce or cease use, and mitigate the 
social, health and legal problems associated with continued 
use. 
The services provided under the heading of “stepped 
care” include community-based prevention and health 
promotion, creating awareness that there are help/treatment 
options for ATS users, self-help groups, brief interventions 
of motivational interviewing and cognitive–behavioural 
therapy (e.g. one to four sessions), intensive individual 
counselling, detoxification and withdrawal services, 
crisis interventions and emergency care, as well as long-
term rehabilitation and reintegration services. Research 
suggests that cognitive–behavioural therapy applied in a 
stepped-care approach is the treatment of best practice for 
ATS use.6
The diagram below summarizes the different levels of 











































6	 National	Drug	Research	Institute.	National Stimulant Strategy Background paper: monograph series No.69.	Australian	Government,	
Department	of	Health	and	Ageing,	2007.	(http://www.health.gov.au/internet/drugstrategy/Publishing.nsf/content/98CFCAEC1A10B
E00CA2574C5000C2641/$File/mono69.pdf,	accessed	01	January	2011).
There are many activities, which need to be undertaken at 
every step.  Thus, case management and counselling are 
important at every stage – though different techniques and 
different intensities are indicated for ATS users, depending 
on their profiles. Also important is the provision of 
opportunities for ATS users to undergo vocational training 
and assistance to gain employment, as well as in improving 
family relations, dealing with legal problems and assisting 
in the development of new recreational activities and social 
networks in the community. 
A. Interventions in the community 
and in primary health-care settings 
(Steps one and two)
Providing services for ATS users in the community is 
the first step. Many ATS users are occasional users who 
require information and education about the risks of ATS 
use, as all ATS users may at some time require emergency 
care and management of acute withdrawal. All ATS users 
should be provided with condoms since ATS use tends to 
increase libido and hence the risk of unsafe sex. Needles 
and syringes should be provided to all ATS injectors.  
Providing services for ATS users in the community and in 
primary health-care settings has many benefits: 
 It helps dispel stigma and discrimination as ATS users 
are not singled out.
 ATS users are exposed to a range of evidence- and 
community-based psychosocial interventions as 
appropriate, without necessarily providing a specific 
therapeutic approach.
 It is a setting where knowledge of community 
resources is available so that referral can easily be 
made to specialized drug treatment facilities or other 
ancillary services.
 It is the setting to which drug users are likely to return 
if referred to specialist care. It is in the community 
that resources for rehabilitation and reintegration are 
mobilized.
 It is the most cost-effective option for ATS users due 
to the lower costs of transportation to such health 
facilities as well as for the health sector in the delivery 
of services to ATS users and associated costs of 
referral to other standard health services such as HIV/
AIDS and tuberculosis.
Nongovernmental outreach workers and community 
primary care nurses are often tasked with initial assessment 
of the severity of drug use of clients. Key determining 
questions should include the following: 
• Pattern and frequency of ATS use
• Use of other substances 
• Perceived consequences or harms. 
A.1	 Psychosocial	interventions
Research into a range of psychosocial interventions has 
yielded some encouraging results.7 The key features of 
7	 Methamphetamine.	Prevention Research Quarterly: Current evidence evaluated, 2008,	24:2.	
8	 Adapted	from:	National Drug Research Institute. National Amphetamine-type Stimulant Strategy Background paper: monograph 
series No.69. 5.1 Amphetamine-type stimulants treatment presentation.	Australian	Government,	Department	of	Health	and	Ageing,	
2007	 (http://www.nationaldrugstrategy.gov.au/internet/drugstrategy/publishing.nsf/Content/mono69-l~mono69-l-ch5~mono69-l-
ch5.1,	accessed	02	January	2011).	
9	 Bandura	A.	Social learning theory.	New	York,	General	Learning	Press,	1977.
10	 Prochaska	JO,	DiClemente	CC.	Trans-theoretical	therapy:	toward	a	more	integrative	model	of	change.	Psychotherapy: Theory, 
Research and Practice,	1982,	19:276–288.






















































successful psychosocial treatment interventions for drug 
problems are as follows:8 
a. Seek the input of drug users to determine what works.
b. Do not blindly apply what seems to work for other 
drug treatment. Interventions must be appropriate. 
Adopt evidence-based approaches. 
c. Adopt a holistic approach that addresses the broader 
socioeconomic issues rather than only the drug use.
 
12	 National	 Drug	 Research	 Institute.	 National	 Amphetamine-type	 Stimulant	 Strategy	 Background	 paper:	 monograph	 series	 No.69.	








Engagement in the treatment process is important 
for ATS users seeking help. Overall, cognitive 
and behavioural approaches, such as motivational 
interviewing, contingency management and relapse 
prevention approaches, have proven to be of value in 
working with ATS users. Treatment may be offered in 
groups or in one-to-one sessions. It may be offered in a 
variety of settings and by diverse health-care providers 
including medical and non-medical health workers, 
NGOs, professional counsellors, peer workers and 
others. These interventions also include harm and risk 
reduction approaches.
 
Brief descriptions of some of the major interventions that 
have been provided to ATS users and for which there is 
encouraging evidence are given in the table on the left. 
The majority of treatment approaches are abstinence-
based and many are too complex for use in primary care. 
It is evident that many of these approaches do, in fact, 
overlap. 
An example of very brief interventions was developed and 
tested in Australia. A two- or four-session combination 
of motivational interviewing and cognitive–behavioural 
therapy was found to significantly increase abstinence 
among dependent methamphetamine users after six 
months. At the six-month follow up, close to half of the 
treatment groups were abstinent compared with only 
30% who received a self-help booklet based on similar 
information.16 
B. Treatment in specialized drug 
treatment facilities – assessment 
and drug dependence treatment 
(Step three)
Drug users suffering from multiple problems and using 
multiple substances, and whose social functioning is 
impaired should be referred for specialist care. This 
is usually provided in specialized drug dependence 
facilities that are of a voluntary nature, i.e. services are 
delivered with informed prior consent of the drug users 
or their legal guardian. 
 
B.1	 Diagnosis:	ATS	dependence	
The diagnosis of amphetamine use and dependence is 
based on criteria listed in the International Classification 
of Diseases (ICD)-10.17 Amphetamine dependence is 
diagnosed if three or more of the following have been 














Around 11% of ATS users may become dependent and 
experience serious problems.18 Dependence is generally 
associated with people who inject or smoke crystalline 
methamphetamine rather than among those who prefer oral 
or intranasal routes of ATS administration. 
Consequences of ATS dependence: ATS dependence 
usually means that more intensive treatment interventions 
are indicated. Potential consequences may include 
paranoid ideation resembling schizophrenia, delusions 
and hallucinations, confusion, psychotic reactions, 
severe anxiety and panic attacks, violence, memory loss, 
aggressive or violent behaviour, mood disturbances, sleep 
disorders and severe weight loss.19
B.2	 Harmful	ATS	use
Somewhat less severe is “harmful use”. ICD-1017 
characterizes it as “a pattern of psychoactive substance 
use that is causing damage to health”. The damage may 
be physical (e.g. hepatitis following the injection of drugs) 
or mental (e.g. depressive episodes secondary to heavy 
alcohol intake). Harmful use commonly, but not 
invariably, has adverse social consequences; social consequences in themselves, however, are 
not sufficient to justify a diagnosis of harmful use.











ATS withdrawal is generally not medically hazardous and fatalities directly attributable to ATS 
withdrawal are rare. The severity of withdrawal is dependent upon the dose and frequency of 
use, type of stimulant used, mode of administration, other drug use, current health problems and 
the duration of use.  Supervision by health-care staff is indicated only in severe cases. 
During and after withdrawal, users must be regularly monitored for their physical and mental 
state as withdrawal can lead to severe depression. Different symptoms become evident at 
different stages of the withdrawal. Thus, antidepressant medication is sometimes indicated for 
a period of three to four weeks after cessation of ATS use, after which time the symptoms 
generally disappear. Adverse consequences and symptoms usually resolve following a period 
of abstinence.    
B.4	 Treatment	of	ATS-induced	psychosis
It has been estimated that the prevalence of psychosis is 11 times higher among regular ATS 
users than among the general population, and that 23% of regular ATS users will experience 
symptoms of psychosis within a given year.21 The treatment of ATS-induced psychosis is 
short -term antipsychotic medication; symptoms usually abate rapidly within days of stopping 
ATS intake. 
B.5	 Intensive	psychotherapy	
As indicated above, for those with severe drug-related problems and those who may also 
experience mental health problems, more intensive interventions are indicated. For example, 
longer-term therapy plus treatment of co-occurring psychiatric and social problems and more 
extended support may be needed. 
17	 International Classification of Mental and Behavioural Disorders (ICD)-10.	Geneva,	World	Health	
Organization,	 1992.	 (http://www.who.int/classifications/icd/en/GRNBOOK.pdf,	 accessed	 02	
January	2011).	
18	 McKetin	R	et	al.	Estimating the number of regular and dependent methamphetamine users in 
Australia Sydney,	National	Drug	and	Alcohol	Research	Centre,	2005	(Technical	Report	No.	230).
19	 UNODC	The	Global	Smart	Programme/Asia	&	Pacific	Amphetamine-Type	Stimulant	Information	
Centre	 (APAIC).	 Long-term effects of methamphetamine abuse.	 2009	 (www.apaic.org/index.
php?option=com_content&view=article&id=120&Itemid=86,	accessed	04	February	2011).	
20	 World	Health	Organization.	Clinical guidelines for withdrawal management and treatment of drug 
dependence in closed settings.	Manila,	WHO	Western	Pacific	Region,	2009.			
21	 Australian	National	Council	on	Drugs	(ANCD).		Methamphetamines: position paper.	Canberra,	
ANCD,	 2007.	 (http://www.ancd.org.au/images/PDF/Positionpapers/pp_methamphetamines.pdf,	
accessed	02	January	2011).
22	 Vocci	 FJ,	 Appel	 NM.	 Approaches	 to	 the	 development	 of	 medications	 for	 the	 treatment	 of	
methamphetamine	dependence.	Addiction,	2007,	102	(Suppl.	1):96–106.
The	 four	 Technical	 Briefs	 on	 Amphetamine-type	 Stimulants	 were	
designed	 by	 the	 WHO	 Regional	 Office	 for	 the	 Western	 Pacific	 in	

























There are as yet no approved pharmacological/substitution 
treatments for ATS users. Potential oral substitution/
pharmacotherapeutic interventions are still in the experimental 
stage but could be useful when they become available for 
chronic and dependent ATS users who are unable to cease use 
or even ameliorate their high-risk behaviours.  
Summing up: the way forward
It is clear that no one treatment modality fits all. Hence, 
it is suggested that a number of interventions be used, in 
which several of the above techniques and approaches are 
integrated and used as appropriate by counsellors. Such 
multimodal approaches adapt behavioural, supportive and 
other techniques to the particular problems of ATS users and, 
as such, are uniquely applicable to their complex needs. A key 
recommendation is to provide ATS users with appropriate 
information about the different treatment options. The search 
for pharmacological approaches is ongoing and when suitable 
treatment becomes available, it will provide an important 
treatment option for ATS users who are as yet unwilling or 
unable to cease ATS use.  
